ATLANTA, March 19 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and tissue processing company, announced today that it will participate in the Sidoti & Company, LLC 13th Annual New York Emerging Growth Institutional Forum at The Grand Hyatt Hotel on Wednesday, March 25, 2009.
D. Ashley Lee, executive vice president, chief operating officer and chief financial officer of CryoLife, Inc., will present a corporate overview at 2:05 p.m. Eastern Time.
A copy of CryoLife's slide presentation will be posted the day of the presentation on the Investor Relations page of www.cryolife.com.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. CryoLife distributes Hemostase MPH, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom, Germany, France, and Canada for cardiac, vascular, and general surgery, subject to certain exclusions.
Media Contacts: D. Ashley Lee Katie Brazel Executive Vice President, Chief Financial Officer and Fleishman Hillard Chief Operating Officer Phone: 404-739-0150 Phone: 770-419-3355
|SOURCE CryoLife, Inc.|
Copyright©2009 PR Newswire.
All rights reserved